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Abstract
Background: Pro-gastrin releasing peptide (ProGRP)
concentrations in blood play an important role in the
diagnosis and treatment of patients with small cell
lung cancer (SCLC). The automated quantitative
ARCHITECT ProGRP assay was developed to aid in
the differential diagnosis and in the management of
SCLC. The purpose of this study was to evaluate the
analytical performance of this chemiluminescent
microparticle immunoassay at multiple sites.
Methods: ARCHITECT ProGRP measures ProGRP
using a two-step sandwich using monoclonal anti-
ProGRP antibodies coated on paramagnetic micro-
particles and labeled with acridinium. Analytical
performance of the assay was evaluated at four sites:
Abbott Japan, Denka Seiken, the Johns Hopkins Uni-
versity, and the University of Munich.
Results: Total precision (%CV) for nine analyte con-
centrations was between 2.2 and 5.7. The analytical
sensitivity of the assay was between 0.20 pg/mL and
0.88 pg/mL. The functional sensitivity at 20% CV was
between 0.66 pg/mL and 1.73 pg/mL. The assay was
linear up to 50,000 pg/mL using a 1:10 autodilution
protocol. The calibration curve was stable for 30 days.
Comparison with the Fujirebio microtiter plate
*Corresponding author: Toru Yoshimura, Research and
Development, Diagnostics Division, Abbott Japan, 278
Matsuhidai, Matsudo, Chiba, Japan
Phone: q81-47-386-4805, Fax: q81-47-386-4257,
E-mail: tohru.yoshimura@abbott.com
Received May 13, 2009; accepted August 11, 2009;
previously published online October 13, 2009
enzyme-linked immunosorbent assay (EIA) ProGRP
assay gave a slope of 0.93 and a correlation coeffi-
cient (r) of 0.99.
Conclusions: These results demonstrate that the
ARCHITECT ProGRP assay has excellent sensitivity,
precision, and correlation to a reference method. This
assay provides a convenient automated method for
ProGRP measurement in serum and plasma in hos-
pitals and clinical laboratories.
Clin Chem Lab Med 2009;47:1557–63.
Keywords: automated immunoassay; chemilumines-
cent microparticle immunoassay; pro-gastrin releas-
ing peptide; small cell lung cancer; tumor marker.
Introduction
Pro-gastrin releasing peptide (ProGRP) is a tumor
marker for small cell lung cancer (SCLC). ProGRP is
used to aid in the diagnosis and monitoring of SCLC.
Gastrin releasing peptide (GRP) is a gut hormone and
is widely distributed in the mammalian gastrointesti-
nal tract, nervous system and pulmonary tract (1–4).
It was reported that GRP was often produced by SCLC
cells, and therefore could be helpful in the diagnosis
of SCLC (5, 6). However, GRP was not useful for diag-
nosis due to poor stability in specimens. Three types
of human ProGRP were found in SCLC cells, with 115,
118, and 125 amino acids (7). ProGRP consists of GRP
(residues 1–27), a cleavage site (residues 28–30), a
constant region (residues 31–98) in the three types of
ProGRP, and a variable carboxy-terminal region that
results from alternative RNA splicing (7, 8).
In 1994, an assay to detect ProGRP (residues 31–98)
in serum was developed because the molecule was
more stable than GRP for clinical use, and increases
in ProGRP were associated with the presence of SCLC
(9–11). The clinical usefulness of ProGRP 31–98 meas-
urements has been reported for diagnosis (9, 11–13),
prediction of prognosis (14), and monitoring of treat-
ment in patients with SCLC (11, 15–17). Neuron-
specific enolase (NSE) has been also used as a tumor
marker for SCLC. However, compared to NSE, Pro-
GRP has relatively high sensitivity and specificity,
and allows early recognition of relapse in patients
with SCLC (11, 18, 19). Also, it was reported that a
combination of ProGRP and NSE gave increased
sensitivity for detection of SCLC (12, 19). The ProGRP
immunoassay was originally developed as a manual
enzyme-linked immunosorbent assay format using
polyclonal and monoclonal antibodies (10, 11). The
assay has been used in the clinical laboratories in
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Figure 1 Format of the ARCHITECT ProGRP assay.
Japan for more than 10 years. However, it has not
been used outside of Japan except for research use.
For worldwide clinical use, the following two impro-
vements would be required: development of an assay
for widely used fully-automated immunoassay ana-
lyzers, and use of monoclonal antibodies for both sol-
id phase and labeled antibodies to assure long-term
reagent reliability.
We describe the development of a fully automated
and highly sensitive immunoassay for the Abbott
ARCHITECT ProGRP (Abbott Japan, Tokyo, Japan).
We used a double monoclonal antibody assay config-
uration for both solid phase and labeled antibody,
with chemiluminescense paramagnetic technology.
We describe the analytical performance of this assay
as evaluated at four sites in the US, Germany and
Japan.
Materials and methods
The ARCHITECT ProGRP assay is a two-step, sandwich for-
mat. Analyte capture is performed with paramagneticmicro-
particles coated with two mouse monoclonal anti-ProGRP
31–98 antibodies: 3G2 (amino acids of ProGRP 84–88) and
2B10 (amino acids of 71–75) (20), which can capture the
C-terminal side of ProGRP 31–98. Detection of the ProGRP
analyte microparticle complex is accomplished with an acri-
dinium labeled mouse monoclonal antibody conjugate. The
mouse monoclonal antibody 3D6-2 (20) can capture the N-
terminal side of the protein (amino acids of ProGRP 40–60).
The antibody profile of the assay is shown in Figure 1.
Exposing the reaction mixture to on-board trigger reagents
containing peroxide at alkaline pH causes light production
that is proportional to the ProGRP concentration. The ARCHI-
TECT ProGRP assay calibrators range from 0 pg/mL to
5000 pg/mL (0, 20, 80, 320, 1250, and 5000 pg/mL). A 1:10
autodilution is used to extend the measurable range
to 50,000 pg/mL. ARCHITECT ProGRP control concentrations
are 40, 160, and 2500 pg/mL. To minimize the risk of inter-
ference from human-anti-mouse antibodies, heterophile
antibodies, and rheumatoid factor, blocking agents and
murine mAbs of different isotypes are used in the assay. In
addition, the F(ab’)2 portion of the antibody, with the Fc por-
tion eliminated by pepsin digestion, was used to produce the
conjugate. The assay is fully automated and measurement
is completed within 30 min with a throughput of 200 tests/h.
ARCHITECT ProGRP assay protocol
The following procedures are performed automatically in the
ARCHITECT instrument: 1) 50 mL of specimen, 50 mL of
microparticle solution, and 20 mL of assay buffer are mixed
and incubated for 18 min at 378C. 2) After a wash step,
50 mL of solution containing the labeled antibody is mixed
and incubated for 4 min at 378C. 3) After another wash step,
the trigger reagent is added and the luminescent signal is
read using a photomultiplier tube. For a 1:10 autodilution,
wash buffer on the instrument is used to dilute the sample.
ProGRP antigen and concentration assignment
Synthetic ProGRP (residues 31–98) peptide (1 pg/mL equals
0.13 pM of ProGRP 31–98) was used for the antigen of
the ARCHITECT calibrator and control reagents (BACHEM
Bioscience Inc, Horizon Drive, King of Prussia, PA, USA).
Since there is no International Standard for ProGRP, the
ARCHITECT ProGRP assay was standardized to match to the
original standard (9) by comparison to the Seramurabo
ProGRP assay kit originally developed by Yamaguchi and
co-workers (9–11).
ProGRP monoclonal antibodies
Hybridomas of the murine anti-ProGRP 31–98 monoclonal
antibodies 3G2, 2B10, and 3D6-2 were provided by Advanced
Life Science Institute, Inc (ALSI; Wako, Japan). The hybrid-
omas were cultured in serum free media and antibodies
were purified with a protein A column from the supernatants
at Abbott Laboratories (Lake County, IL, USA).
Magnetic microparticles
Murine anti-ProGRP 31–98 antibodies of 3G2 and 2B10
were coated on to the carboxylated magnetic microparticle
(Polymer Laboratories, Shropshire, UK) surface with N-Ethyl-
N’-(3-Dimethylaminopropyl)carbodiimide (Sigma-Aldrich,St.
Louis, MO, USA) as a coupling substance. The coating with
two antibodies increased analytical sensitivity of the assay
;10 fold when compared to use of a single monoclonal
antibody.
Specimens
SCLC specimens were obtained from Johns Hopkins Uni-
versity, ProMeDx, LLC (Norton, MA, USA), Clinical Research
Center of Cape Cod, Inc (West Yarmouth, MA, USA), and
Teragenix (Ft. Lauderdale, FL, USA). Normal specimens from
Yoshimura et al.: Analytical performance of an automated ProGRP assay 1559
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apparently healthy individuals were obtained from ProMeDx,
LLC. These specimens were stored frozen at –208C or colder
until use. The specimens were collected under an institu-
tional review board approved protocol.
Evaluation methods
Precision was evaluated using serum and plasma specimens
spiked with synthetic ProGRP 31–98 antigen and the ARCHI-
TECT ProGRP controls. These were measured in duplicate,
two times per day for 20 days in accordance with the Clinical
and Laboratory Standards Institute (CLSI, protocol EP5-A2).
A high plasma specimen spiked with synthetic ProGRP
31–98 antigen at ;30,000 pg/mL level was tested using the
1:10 autodilution protocol.
Dilution linearity studies were conducted with native
high titer serum specimens (614 pg/mL and 3337 pg/mL) and
with serum (276–4676 pg/mL) and plasma (226–4931 pg/mL)
specimens spiked with synthetic ProGRP 31–98 antigen.
Specimens were serially diluted in 10% increments with the
ARCHITECT A calibrator (0 pg/mL ProGRP). Regression anal-
yses of the observed diluted concentrations were compared
to target values based on the corresponding concentration
of the undiluted specimen.
We evaluated manual vs. automated dilutions by calculat-
ing the % difference of a instrument-diluted specimen (1:10
on the ARCHITECT system) compared with a manually dilut-
ed specimens. Specimens containing more than 5000 pg/mL
of ProGRP (three of native high titer SCLC sera, four of
serum and seven plasma specimens spiked with ProGRP
31–98) were evaluated.
Within-assay specimen carryover was tested by alternat-
ing a low serum specimen (;10 pg/mL ProGRP) with a high
serum specimen (;110,000 pg/mL) spiked with ProGRP
31–98, and repeated 10 times. The % carryover was deter-
mined by calculating the % difference in value of the low
specimen run immediately after the high specimen.
The absence of a high-dose hook effect was confirmed by
testing specimens beyond the dynamic range of the assay
(5000 pg/mL) up to 100,000 pg/mL to determine whether
signal suppression occurs at analyte levels exceeding the
concentration levels of the assay calibration.
Analytical sensitivity was determined with five runs of ten
replicates of the A calibrator (0 pg/mL) and four replicates of
B calibrator (20 pg/mL). The following calculation was used:
analytical sensitivitysstandard deviation (SD) A calibrator=
2=w20 pg/mL B calibrator level/(B calibrator average relative
light unit (RLU) – A calibrator average RLU)x.
The functional sensitivity was evaluated using a set of dilu-
tion panels made by diluting a normal specimen with the A
calibrator. The panel members were tested in replicates of
10 for 5 days. The ProGRP concentration that showed 20%
CV with linear least square regression plotted between total
precision (%CV) and (1/ProGRP concentration) was defined
as the functional sensitivity.
Recovery was evaluated by spiking ProGRP from a high-
titer serum from a patient with SCLC into matched serum,
ethylenediaminetetraacetic acid (EDTA) plasma and heparin
plasma samples. The ProGRP values were measured with
the ARCHITECT ProGRP assay. Percent recovery was calcu-
lated using the following formula: (% recovery)sw(observed
concentration of sample spiked ProGRP serum)–(concen-
tration of the unspiked sample)x/(ProGRP concentration add-
ed). Note that calibrator buffer was added to the unspiked
sample to maintain the same volume as the spiked sample.
Reagent on-board stability studies were conducted using
serum and plasma specimens spiked with synthetic ProGRP
31–98 antigen and the ARCHITECT ProGRP controls. A cali-
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Table 2 Analytical sensitivity and functional sensitivity at 20% CV.
(A) Analytical sensitivity with 2 SD method
Analytical sensitivity, pg/mL
Lot I Lot II Lot III
Site 1 (Instrument 1) 0.20 0.21 0.25
Site 1 (Instrument 2) 0.27 0.23 0.40
Site 3 (Instrument 3) 0.88 0.51 0.60
Average 0.39
(B) Functional sensitivity at 20% CV
Functional sensitivity, pg/mL
Lot I Lot II Lot III
Site 1 (Instrument 1) 0.68 0.66 0.92
Site 1 (Instrument 2) 1.25 1.03 1.17
Site 3 (Instrument 3) 1.73 1.16 1.61
Average 1.13
Table 3 Recovery of ProGRP spiked into EDTA plasma, heparin plasma, and serum.
Specimen type Recovery Average recovery, %
Spiked ProGRP concentration
50 pg/mL, % 150 pg/mL, %
EDTA plasma-1 91.3 92.5
EDTA plasma-2 95.6 94.3
EDTA plasma-3 92.0 95.7 93.9
EDTA plasma-4 96.2 92.2
EDTA plasma-5 96.6 92.8
Heparin plasma-1 95.8 98.4
Heparin plasma-2 95.5 98.7
Heparin plasma-3 104.5 102.1 97.8
Heparin plasma-4 97.3 96.9
Heparin plasma-5 96.0 93.2
Serum-1 88.9 87.2
Serum-2 91.9 97.7
Serum-3 96.5 97.0 92.8
Serum-4 91.2 91.2
Serum-5 92.3 93.6
bration curve was established at the initiation of the 31 days
study and used to generate concentrations for each samples
with reagents stored at 2–88C off the instrument (Control),
and stored at 2–88C on-board the instrument for the duration
of the study (Test). Baseline was calculated as the mean of
the first five timepoints with the control reagent. Specimen
and control concentrations were evaluated for trending over
time in control and test reagents using Westgard rules (21).
Calibration curve storage was calculated using data gen-
erated from the control reagents tested for on-board stabil-
ity. The percent change in RLUs and concentrations for
specimens tested on day 31 were compared to the RLUs and
concentrations from the calibration performed at the initia-
tion of the study.
Assay interferences were evaluated using chemotherapeu-
tic drugs at two times their peak blood level, with common
interfering substances and GRP, as shown in Table 4.
Though amino acid sequence between GRP and ProGRP
31–98 is completely different, interference of large amounts
of GRP was evaluated to confirm that there was no cross
reactivity to GRP. Each drug or potentially interfering sub-
stance was tested in three normal serum specimens and
three normal plasma specimens spiked with 50 or 150 pg/mL
of ProGRP from a high-titer specimen. Ten replicates were
tested on the ARCHITECT ProGRP assay for each of the test
and control specimens.
Correlation between the microtiter plate enzyme immu-
noassay of the Seramurabo ProGRP assay from Fuji-rebio
(Tokyo, Japan) and the ARCHITECT ProGRP was evaluated
using 64 SCLC and 192 normal specimens. The first ProGRP
assay was co-developed by the National Cancer Center
(Tokyo, Japan), Terumo Corp. (Kanagawa, Japan), and
Tonen Corp. (Saitama, Japan; 9, 10, 11, 13). The kit was
approved for use in Japan as a diagnostic product and is
now provided by Fuji-rebio. Also, the kit is available in
Europe and the US as a research use only product provided
by ALSI.
Evaluation sites
Evaluation was performed at four sites: (1) Abbott Japan
(Matsudo-city, Chiba, Japan), (2) Denka Seiken (Gosen-
city, Niigata, Japan), (3) The Johns Hopkins University (Bal-
timore, Maryland, USA) and (4) University of Munich
(Munich, Germany).
Results
Total precision for the ARCHITECT ProGRP assay
evaluated over 20 days at four sites with three lots of
Yoshimura et al.: Analytical performance of an automated ProGRP assay 1561
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Figure 2 Reagent on-board instrument stability with control
L and serum panel L.
Table 4 Evaluation of common interfering substances, anticancer chemotherapeutic drugs, and GRP.
Interference
Specimen type Average, %
Serum, % Plasma, %
Bilirubin, 20 mg/dL (0.34 mmol/L) 0.3 0.2 0.3
Hemoglobin, 5 g/L –8.5 –3.5 –6.0
Total protein, 120 g/L –2.0 –2.2 –2.1
Total protein, 30 g/L –2.5 –2.8 –2.7
Red blood cells, 4 mL/mL ND –4.9 –4.9
Triglycerides, 30 g/L 3.9 5.9 4.9
Carboplatin, 110.8 mg/mL –0.9 –0.3 –0.6
Cisplatin, 7.24 mg/mL 0.4 –1.1 –0.3
Cyclophosphamide, 4.08 mg/mL –1.3 2.2 0.4
Docetaxel, 4.6 m/mL –0.5 –1.2 –0.8
Doxorubicin, 360 mM –1.3 –0.2 –0.7
Etoposide, 80 mg/mL –0.8 0.3 –0.2
Gemcitabine, 43.7 mg/mL 0.5 0.5 0.5
Ifosfamide, 0.78 mg/mL 1.9 0.0 0.9
Irinotecan, 11.5 mg/mL 0.8 –0.2 0.3
Paclitaxel, 13.5 ng/mL 2.1 –1.5 0.3
Topotecan, 172.2 ng/mL 2.2 2.0 2.1
Vincristine, 140 ng/mL 1.0 0.4 0.7
Vinorelbine, 2000 ng/mL 0.3 0.4 0.3
GRP, 100 ng/mL 1.1 1.2 1.2
ND, not determined.
reagents on four instruments, and using nine speci-
mens ranging from 40 to 3729 pg/mL is shown in
Table 1. The total precision ranged from 2.2% to 5.7%
CV for serum and plasma. The total precision for the
automated dilution evaluated at one site with three
lots of reagents on two instruments ranged from
3.7% to 5.1% CV using specimens spiked to contain
28,972 pg/mL ProGRP. The average 1:10 autodilution
protocol results were –5.8% and –7.6% of the manu-
ally diluted results with six sera and seven plasma
specimens, respectively, using native and spiked
specimens contained between 6220 and 40,491 pg/mL
of ProGRP.
Dilution linearity studies using specimens with con-
centrations ranging from 25.8 to 4931 pg/mL showed
correlation coefficients ranging from 0.9964 to 0.9994.
Mean recoveries of diluted samples ranged from 93%
to 107% (average 103%) in six spiked serum speci-
mens, and 98% to 111% (average 102%) in six spiked
plasma specimens. Mean recoveries of two SCLC sera
were 102% and 104%. Dilutions were linear through-
out the calibration curve range down to the lowest
calibrator. The ARCHITECT ProGRP assay dilutes lin-
early with a mean recovery 2.6% from the target.
The mean within-assay specimen carryover evalu-
ated with two instruments was 2.1 pg/mL (19 ppm)
after a specimen with 110,000 pg/mL.
Assessment of high dose hook effect showed that
all five specimens with ProGRP )5000 pg/mL yielded
test results )5000 pg/mL. No signal suppression or
high dose hook effect was observed up to 100,000
pg/mL.
Analytical sensitivity and the functional sensitivity
evaluated at two sites with three lots of reagents on
three instruments are shown in Table 2A and B. The
average analytical sensitivity was 0.39 pg/mL and
ranged from 0.20 to 0.88 pg/mL. The average func-
tional sensitivity at a 20% CV was 1.13 pg/mL and
ranged from 0.66 to 1.73 pg/mL.
The calculated recovery in the ARCHITECT ProGRP
assay after spiking a high-titer ProGRP specimen into
matched serum, EDTA plasma, and heparin plasma
specimens is shown in Table 3. The average percent
recovery was 92.8%, 93.9%, and 97.8% with serum,
EDTA plasma, and heparin plasma, respectively.
Reagent on-board stability studies were conducted
at two sites with three lots of reagents using two
instruments and nine specimens with low, medium,
1562 Yoshimura et al.: Analytical performance of an automated ProGRP assay
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Figure 3 Correlation between the manual Seramurabo
ProGRP EIA assay and the ARCHITECT ProGRP assay.
and high concentrations of spiked serum and plasma,
and ARCHITECT controls. Results showed no signifi-
cant changes from study baseline up to 30 days using
Westgard rules. Two examples of the results are illus-
trated in Figure 2A and B.
The effects of potential interfering substances and
drugs are presented in Table 4. Chemotherapeutic
agents at twice their peak blood levels had interfer-
ences of –0.8% to q2.1%. Increased bilirubin, total
protein, triglycerides, red blood cells and hemoglobin,
and low total protein showed interference effects
from –6.0% to q4.9%.
Correlation between the first commercial ProGRP
assay, Seramurabo ProGRP, and the ARCHITECT
ProGRP is presented in Figure 3. The slope, calculated
using the Passing-Bablok regression method was 0.93
with a correlation coefficient of rs0.99.
Discussion
ProGRP is used as a marker for the differential diag-
nosis and monitoring of SCLC. It is important to dis-
tinguish between SCLC and non-SCLC due to differ-
ences in prognosis and treatment. SCLC accounts for
15%–25% of new cases of lung cancer, is an aggres-
sive and rapidly growing neoplasm that tends to be
disseminated at early stage of the disease. However,
this cancer is highly sensitive to systemic chemother-
apy. ProGRP was developed as a tumor marker in
1994 for patients with SCLC (9). It has been clinically
used as a tumor marker in Japan since 1996 for aid
in the diagnosis, monitoring of treatment, and early
detection of relapse. However, it has been available
as a research-use only manual assay outside of
Japan. This tumor marker plays a very important role
in the management of this cancer. The development
of this fully automated immunoassay using monoclo-
nal antibodies can support the global use of ProGRP
for management of SCLC.
The multi-site evaluation studies for the ARCHITECT
ProGRP assay reported here demonstrated good ana-
lytical precision, accuracy and sensitivity. The assay
has a range, with the 1:10 autodilution, of 50,000
pg/mL, with no hook effect observed at 100,000
pg/mL. The reagents and calibration curve were sta-
ble onboard the instrument for 30 days. The assay
demonstrated robustness to potential interfering
substances including chemotherapeutic drugs and a
variety of compounds commonly assessed for inter-
ference in immunoassays. The assay correlated well
to the existing manual ProGRP assay.
The ARCHITECT ProGRP assay was designed to be
used with plasma as well as serum samples. The
assay demonstrates good recovery, dilution linearity
and precision with plasma. The ability to test plasma
ProGRP is important based on the recent observa-
tions demonstrating improved specimen stability for
plasma ProGRP when compared to serum ProGRP
(22).
In conclusion, the ARCHITECT ProGRP assay dem-
onstrated convenient, high throughput and good
analytical performance necessary for ProGRP meas-
urements used to aid in the differential diagnosis and
monitoring of SCLC. This assay provides a convenient
automated method for measurement of ProGRP in
serum and plasma in hospitals and clinical laborato-
ries. Additional clinical studies in Europe and Japan
using the ARCHITECT ProGRP are currently underway
to better define its use for the management of
patients with SCLC.
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